Evidence map›Paper›PMID 42657972›Full record

ArticlePharmacology research & perspectives2026

Preclinical and Toxicology Studies of LPM7100328, a Novel Oral GnRH Antagonist.

Yao Wang, Junxian Zhao, Fangxia Zou, Wanglin Jiang, Jianzhao Zhang, Pengfei Yu, Liang Ye, Xiaolin Sun, Chunmei Li, Jingwei Tian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yao WangKey Laboratory of Molecular Pharmacology and Drug Evaluation, School of Pharmacy, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong, China.ORCID https://orcid.org/0009-0000-0489-5209
Junxian ZhaoBeijing Peking University WBL Biotech Co. Ltd., Beijing, China.
Fangxia ZouKey Laboratory of Molecular Pharmacology and Drug Evaluation, School of Pharmacy, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong, China.
Wanglin JiangState Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co. Ltd., Yantai, Shandong, China.
Jianzhao ZhangState Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co. Ltd., Yantai, Shandong, China.
Pengfei YuState Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co. Ltd., Yantai, Shandong, China.
Liang YeState Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong Luye Pharmaceutical Co. Ltd., Yantai, Shandong, China.
Xiaolin SunKey Laboratory of Molecular Pharmacology and Drug Evaluation, School of Pharmacy, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong, China.
Chunmei LiKey Laboratory of Molecular Pharmacology and Drug Evaluation, School of Pharmacy, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong, China.
Jingwei TianKey Laboratory of Molecular Pharmacology and Drug Evaluation, School of Pharmacy, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong, China.

Funding

Major Basic Research Special Projects of Shandong Provincial, China ZR2024ZD21Natural Science Foundation of Shandong Province, China ZR2025MS1445Natural Science Foundation of Shandong Province, China ZR2025QC881
6 · The paper itself

Abstract

LPM7100328 is a novel oral GnRH antagonist being developed for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. The studies presented herein reported assessment of safety in favor of human clinical trials. Safety pharmacology studies showed that LPM7100328 had no adverse pharmacological effects. No apparent abnormalities were observed in 28-day rat and dog toxicity study, the no observed adverse effect level (NOAEL) was 100 mg/kg and 50 mg/kg, respectively. LPM7100328 was found to be non-genotoxic in the Ames, aberration test or micronucleus assay. In the rat fertility and early embryonic development study and rabbit fertility and embryo-fetal development study, LPM7100328 demonstrated a generally favorable safety profile, with no teratogenic effects observed in either species. And LPM7100328 showed no phototoxicity. Collectively, these findings indicate a favorable nonclinical safety profile for LPM7100328 in the prevention of premature LH surges during women undergoing controlled ovarian stimulation.

Indexed as

Gonadotropin-Releasing HormoneHormone AntagonistsAdministration, OralAnimalsDogsDrug Evaluation, PreclinicalEmbryonic DevelopmentFemaleFertilityHumansLuteinizing HormoneNo-Observed-Adverse-Effect LevelOvulation InductionRabbitsRatsGonadotropin-Releasing HormoneHormone AntagonistsLuteinizing Hormonecontrolled ovarian stimulationGnRH antagonistLPM7100328safetytoxicology

Identifiers

PMID42657972
PMCPMC13520795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.